Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVR NASDAQ:LMAT NASDAQ:SLNO NASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVRAnteris Technologies Global$9.62+6.9%$6.17$2.85▼$9.79$936.43M1.32963,383 shs2.35 million shsLMATLeMaitre Vascular$97.75-1.8%$108.54$78.35▼$118.01$2.23B0.6274,589 shs207,218 shsSLNOSoleno Therapeutics$53.01$46.32$29.43▼$90.32$2.76B-2.221.75 million shsN/ATMDXTransMedics Group$68.93+0.1%$98.18$60.10▼$156.00$2.38B2.071.92 million shs1.15 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVRAnteris Technologies Global0.00%+32.87%+73.96%+69.37%+170.22%LMATLeMaitre Vascular0.00%+0.45%-13.42%+5.18%+19.94%SLNOSoleno Therapeutics0.00%0.00%+0.34%+34.68%-27.68%TMDXTransMedics Group0.00%+9.07%-39.11%-48.66%-43.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVRAnteris Technologies Global$9.62+6.9%$6.17$2.85▼$9.79$936.43M1.32963,383 shs2.35 million shsLMATLeMaitre Vascular$97.75-1.8%$108.54$78.35▼$118.01$2.23B0.6274,589 shs207,218 shsSLNOSoleno Therapeutics$53.01$46.32$29.43▼$90.32$2.76B-2.221.75 million shsN/ATMDXTransMedics Group$68.93+0.1%$98.18$60.10▼$156.00$2.38B2.071.92 million shs1.15 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVRAnteris Technologies Global0.00%+32.87%+73.96%+69.37%+170.22%LMATLeMaitre Vascular0.00%+0.45%-13.42%+5.18%+19.94%SLNOSoleno Therapeutics0.00%0.00%+0.34%+34.68%-27.68%TMDXTransMedics Group0.00%+9.07%-39.11%-48.66%-43.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVRAnteris Technologies Global 2.60Moderate Buy$16.0066.32% UpsideLMATLeMaitre Vascular 2.75Moderate Buy$112.6015.19% UpsideSLNOSoleno Therapeutics 2.08Hold$76.6744.63% UpsideTMDXTransMedics Group 2.50Moderate Buy$135.0095.85% UpsideCurrent Analyst Ratings BreakdownLatest AVR, SLNO, TMDX, and LMAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026LMATLeMaitre Vascular Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/19/2026SLNOSoleno Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral5/15/2026AVRAnteris Technologies Global BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$17.00 ➝ $18.005/11/2026SLNOSoleno Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/6/2026LMATLeMaitre Vascular Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)5/6/2026LMATLeMaitre Vascular Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$105.00 ➝ $120.005/6/2026LMATLeMaitre Vascular Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$118.00 ➝ $127.005/6/2026LMATLeMaitre Vascular Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$94.00 ➝ $104.005/6/2026TMDXTransMedics Group Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$152.00 ➝ $124.005/6/2026TMDXTransMedics Group TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$190.00 ➝ $120.005/6/2026TMDXTransMedics Group Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$130.00 ➝ $85.00(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVRAnteris Technologies Global$1.91M490.27N/AN/A$2.86 per share3.36LMATLeMaitre Vascular$249.60M8.95$2.90 per share33.68$17.80 per share5.49SLNOSoleno Therapeutics$285.01M9.69$0.43 per share124.10$9.51 per share5.57TMDXTransMedics Group$635.89M3.75$3.93 per share17.55$14.29 per share4.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVRAnteris Technologies Global-$94.14M-$2.23N/AN/AN/A-5,148.78%-124.76%-101.21%8/10/2026 (Estimated)LMATLeMaitre Vascular$57.73M$2.7136.0729.892.7224.35%15.36%9.78%8/4/2026 (Estimated)SLNOSoleno Therapeutics$20.89M$1.7729.959.89N/A33.70%22.85%18.25%8/5/2026 (Estimated)TMDXTransMedics Group$190.29M$4.4015.6718.99N/A27.04%22.38%8.46%7/30/2026 (Estimated)Latest AVR, SLNO, TMDX, and LMAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026AVRAnteris Technologies Global-$0.2708-$0.28-$0.0092-$0.28$0.77 million$0.49 million5/5/2026Q1 2026LMATLeMaitre Vascular$0.66$0.68+$0.02$0.68$66.67 million$66.55 million5/5/2026Q1 2026TMDXTransMedics Group$0.62$0.30-$0.32$0.20$174.44 million$173.93 million2/26/2026H2 2025AVRAnteris Technologies GlobalN/A-$0.75N/A-$0.75N/A$0.31 million2/25/2026Q4 2025LMATLeMaitre Vascular$0.67$0.68+$0.01$0.68$62.98 million$64.45 million2/25/2026Q4 2025SLNOSoleno Therapeutics$0.64$0.80+$0.16$0.80$88.55 million$91.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVRAnteris Technologies GlobalN/AN/AN/AN/AN/ALMATLeMaitre Vascular$1.001.02%+16.05%36.90%14 YearsSLNOSoleno TherapeuticsN/AN/AN/AN/AN/ATMDXTransMedics GroupN/AN/AN/AN/AN/ALatest AVR, SLNO, TMDX, and LMAT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/28/2026LMATLeMaitre Vascularquarterly$0.251%5/21/20265/21/20266/4/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVRAnteris Technologies GlobalN/A20.9320.93LMATLeMaitre Vascular0.4214.3212.20SLNOSoleno Therapeutics0.105.625.32TMDXTransMedics Group1.706.746.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVRAnteris Technologies GlobalN/ALMATLeMaitre Vascular84.64%SLNOSoleno Therapeutics97.42%TMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipAVRAnteris Technologies Global4.50%LMATLeMaitre Vascular7.40%SLNOSoleno Therapeutics6.40%TMDXTransMedics Group6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVRAnteris Technologies Global13897.34 million92.96 millionN/ALMATLeMaitre Vascular49022.85 million21.16 millionOptionableSLNOSoleno Therapeutics3052.12 million48.78 millionOptionableTMDXTransMedics Group21034.56 million32.18 millionOptionableAVR, SLNO, TMDX, and LMAT HeadlinesRecent News About These CompaniesHead to Head Comparison: TransMedics Group (NASDAQ:TMDX) vs. Pressure BioSciences (OTCMKTS:PBIO)May 22 at 4:49 AM | americanbankingnews.comTransMedics Shareholders Reelect Board and Approve Executive PayMay 21 at 6:30 PM | tipranks.comTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 21 at 4:05 PM | prnewswire.comTransMedics Group Signals Growth Amid Margin SqueezeMay 21 at 12:15 PM | theglobeandmail.comTransMedics Group (NASDAQ:TMDX) Gains Momentum In Healthcare SpaceMay 19, 2026 | kalkinemedia.comKTransMedics to Present at the William Blair 46th Annual Growth Stock ConferenceMay 19, 2026 | prnewswire.comTransMedics Group (NASDAQ:TMDX) Shares Up 7.1% - Here's What HappenedMay 18, 2026 | marketbeat.comTransMedics Group (TMDX) price target decreased by 22.22% to 126.07May 14, 2026 | msn.comTransMedics Group (NASDAQ:TMDX) Reaches New 52-Week Low - Here's WhyMay 12, 2026 | marketbeat.comAssessing TransMedics Group (TMDX) Valuation After A Sharp One Year Share Price DeclineMay 11, 2026 | finance.yahoo.comWall Street Zen Downgrades TransMedics Group (NASDAQ:TMDX) to SellMay 9, 2026 | marketbeat.comTransMedics Group, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 8, 2026 | seekingalpha.comTransMedics Group Inc (TMDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...May 8, 2026 | finance.yahoo.comTransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of "Moderate Buy" by BrokeragesMay 8, 2026 | marketbeat.comTransMedics Group (TMDX) Gets a Buy from NeedhamMay 7, 2026 | theglobeandmail.comTransMedics Group Stock Watch: Healthcare Growth in FocusMay 6, 2026 | kalkinemedia.comKTransMedics tumbles after earnings missMay 6, 2026 | seekingalpha.comTransMedics: Cheaper, But Still Priced For PerfectionMay 6, 2026 | seekingalpha.comTransMedics Group (NASDAQ:TMDX) Given New $124.00 Price Target at Canaccord Genuity GroupMay 6, 2026 | marketbeat.comTransMedics Group (NASDAQ:TMDX) Price Target Lowered to $120.00 at TD CowenMay 6, 2026 | marketbeat.comStifel Nicolaus Cuts TransMedics Group (NASDAQ:TMDX) Price Target to $85.00May 6, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVR, SLNO, TMDX, and LMAT Company DescriptionsAnteris Technologies Global NASDAQ:AVR$9.62 +0.62 (+6.89%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$9.65 +0.03 (+0.35%) As of 05/22/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.LeMaitre Vascular NASDAQ:LMAT$97.75 -1.77 (-1.78%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$97.69 -0.06 (-0.06%) As of 05/22/2026 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.Soleno Therapeutics NASDAQ:SLNO$53.01 0.00 (0.00%) As of 05/19/2026Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.TransMedics Group NASDAQ:TMDX$68.93 +0.08 (+0.12%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$68.53 -0.40 (-0.58%) As of 05/22/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
